Long-Term Effects of Adjuvant Tamoxifen and/or Radiotherapy: The South Sweden Breast Cancer Trial

Authors:
  • MFMårten Fernö
    Mårten Fernö
  • TMTorgil Möller
    Torgil Möller
  • KAKnut Aspegren
    Knut Aspegren
  • LBLars Bergljung
    Lars Bergljung
  • DKDick Killander
    Dick Killander
  • TLTorsten Landberg
    Torsten Landberg

Abstract
In a multicenter trial of adjuvant therapy in stage II breast cancer, 719 postmenopausal patients were randomized to one of three treatment regimens: radiotherapy only or in combination with adjuvant tamoxifen for one year, or adjuvant tamoxifen without radiotherapy. At twelve years of follow-up (median 9 years), no statistically significant differences in survival or recurrence-free survival were observed. However, the rate of loco-regional recurrency was lower among patients treated with both radiotherapy and tamoxifen. The rate of bilateral breast cancer was reduced in tamoxifen-treated patients whereas the rate of new primary malignancies other than breast cancer was somewhat higher in tamoxifen-treated patients. Adjuvant therapy in breast cancer may influence not only breast cancer recurrences and mortality but also later disease patterns and cause-specific mortality.

This publication has 11 references indexed in Scilit: